Preoperative prediction of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: a Canadian single-Centre experience.


Journal

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
ISSN: 1916-0216
Titre abrégé: J Otolaryngol Head Neck Surg
Pays: England
ID NLM: 101479544

Informations de publication

Date de publication:
02 Jan 2020
Historique:
received: 06 12 2018
accepted: 23 12 2019
entrez: 4 1 2020
pubmed: 4 1 2020
medline: 22 9 2022
Statut: epublish

Résumé

An international group of experts recommended reclassifying non-invasive follicular variant of papillary thyroid cancers (FVPTC) as 'non-invasive follicular thyroid neoplasm with papillary-like nuclear features' (NIFTP) in April 2016. The purpose of this study was to establish preoperative clinical, laboratory, ultrasonographic, and cytological variables, which can differentiate NIFTP from FVPTC. We conducted a retrospective chart review of consecutive patients from a single institution evaluated between January 2012 and December 2017. 203 adult patients underwent lobectomy or total thyroidectomy for a FVPTC during that period. Each patient's medical chart was reviewed and information on pre-operative variables was recorded. An expert pathologist reviewed all surgical specimens and reclassified a subset of FVPTC as NIFTP according to the specific criteria. Overall, 44 patients were included in the NIFTP group and 159 in the non-NIFTP group. Mean age was 50.1 years in the NIFTP group and 50.7 in the non-NIFTP group. Most patients were female (86.4% (38/44) in the NIFTP group vs 79.8% (127/159) in the non-NIFTP group). More patients underwent lobectomy in the NIFTP group (50% (22/44) vs 16.4% (26/159) in the non-NIFTP group, p = < 0.0001). Less patients received radioactive iodine in the NIFTP group (31.8% (14/44) vs 52.2% (83/159) in the non-NIFTP group, p = 0.0177). Preoperative thyroglobulin levels were lower in NIFTP patients (Median 25.55 mcg/L +/- 67.8 vs 76.06 mcg/L +/- 119.8 in Non-NIFTP, p = 0.0104). NIFTP nodules were smaller (Mean size 22.97 mm +/- 12.3 vs 25.88 mm +/- 11.2 for non-NIFTP, p = 0.0448) and more often solid than non-NIFTP (93.2% (41/44) vs 74.8% (119/159) for non-NIFTP, p = 0.0067). 2017 ACR TIRADS nodule category of 1-4 on ultrasound had a negative predictive value and a sensitivity of 100% for NIFTP. ROC Curve Analysis demonstrated that a preoperative thyroglobulin level of 31.3 mcg/L had a sensitivity of 75% and a specificity of 62.5% to differentiate NIFTP from non-NIFTP cancers. Lower preoperative thyroglobulin levels, smaller nodule size, solid texture and 2017 ACR TIRADS Category of 1-4 are more strongly associated with NIFTP than FVPTC and can favour less invasive surgical options such as lobectomy.

Sections du résumé

BACKGROUND BACKGROUND
An international group of experts recommended reclassifying non-invasive follicular variant of papillary thyroid cancers (FVPTC) as 'non-invasive follicular thyroid neoplasm with papillary-like nuclear features' (NIFTP) in April 2016. The purpose of this study was to establish preoperative clinical, laboratory, ultrasonographic, and cytological variables, which can differentiate NIFTP from FVPTC.
METHODS METHODS
We conducted a retrospective chart review of consecutive patients from a single institution evaluated between January 2012 and December 2017. 203 adult patients underwent lobectomy or total thyroidectomy for a FVPTC during that period. Each patient's medical chart was reviewed and information on pre-operative variables was recorded. An expert pathologist reviewed all surgical specimens and reclassified a subset of FVPTC as NIFTP according to the specific criteria.
RESULTS RESULTS
Overall, 44 patients were included in the NIFTP group and 159 in the non-NIFTP group. Mean age was 50.1 years in the NIFTP group and 50.7 in the non-NIFTP group. Most patients were female (86.4% (38/44) in the NIFTP group vs 79.8% (127/159) in the non-NIFTP group). More patients underwent lobectomy in the NIFTP group (50% (22/44) vs 16.4% (26/159) in the non-NIFTP group, p = < 0.0001). Less patients received radioactive iodine in the NIFTP group (31.8% (14/44) vs 52.2% (83/159) in the non-NIFTP group, p = 0.0177). Preoperative thyroglobulin levels were lower in NIFTP patients (Median 25.55 mcg/L +/- 67.8 vs 76.06 mcg/L +/- 119.8 in Non-NIFTP, p = 0.0104). NIFTP nodules were smaller (Mean size 22.97 mm +/- 12.3 vs 25.88 mm +/- 11.2 for non-NIFTP, p = 0.0448) and more often solid than non-NIFTP (93.2% (41/44) vs 74.8% (119/159) for non-NIFTP, p = 0.0067). 2017 ACR TIRADS nodule category of 1-4 on ultrasound had a negative predictive value and a sensitivity of 100% for NIFTP. ROC Curve Analysis demonstrated that a preoperative thyroglobulin level of 31.3 mcg/L had a sensitivity of 75% and a specificity of 62.5% to differentiate NIFTP from non-NIFTP cancers.
CONCLUSION CONCLUSIONS
Lower preoperative thyroglobulin levels, smaller nodule size, solid texture and 2017 ACR TIRADS Category of 1-4 are more strongly associated with NIFTP than FVPTC and can favour less invasive surgical options such as lobectomy.

Identifiants

pubmed: 31898554
doi: 10.1186/s40463-019-0397-9
pii: 10.1186/s40463-019-0397-9
pmc: PMC6941342
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1

Références

Thyroid. 2016 Oct;26(10):1466-1471
pubmed: 27457786
Am J Clin Pathol. 2015 Dec;144(6):850-7
pubmed: 26572991
Clin Endocrinol (Oxf). 2018 Jan;88(1):114-122
pubmed: 28898488
Endocr Relat Cancer. 2016 Dec;23(12):893-897
pubmed: 27660403
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
Thyroid. 2018 Feb;28(2):210-219
pubmed: 29160163
Hum Pathol. 2016 Aug;54:134-42
pubmed: 27085556
Horm Metab Res. 2015 Apr;47(4):247-52
pubmed: 25384015
Pediatr Blood Cancer. 2015 Nov;62(11):1942-6
pubmed: 26131690
Ann Surg Oncol. 2017 Oct;24(11):3300-3305
pubmed: 28801882
Thyroid. 2015 Sep;25(9):987-92
pubmed: 26114752
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Otolaryngol Head Neck Surg. 2010 Dec;39(6):669-73
pubmed: 21144363
Cancer Cytopathol. 2016 Oct;124(10):699-710
pubmed: 27717284
J Am Coll Radiol. 2017 May;14(5):587-595
pubmed: 28372962
Am J Clin Pathol. 2016 Sep;146(3):373-7
pubmed: 27543982
Clin Endocrinol (Oxf). 2017 Mar;86(3):444-450
pubmed: 27761926
J Korean Med Sci. 2012 Sep;27(9):1014-8
pubmed: 22969246
Endocr J. 2017 Dec 28;64(12):1149-1155
pubmed: 28904306
Thyroid. 2017 Apr;27(4):481-483
pubmed: 28114862
Thyroid. 2018 Mar;28(3):311-318
pubmed: 29343212
Cancer Cytopathol. 2016 Mar;124(3):181-7
pubmed: 26457584
Hum Pathol. 2015 May;46(5):657-64
pubmed: 25721865

Auteurs

Vincent Larouche (V)

Division of Endocrinology and Metabolism, Jewish General Hospital, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada. Vincent.larouche@mail.mcgill.ca.

Marc Philippe Pusztaszeri (MP)

Division of Pathology, Jewish General Hospital, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada.

Sabin Filimon (S)

Internal Medicine Residency Training Program, McGill University, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada.

Richard Payne (R)

Division of Oto-Rhino-Laryngology, Jewish General Hospital, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada.

Michael Hier (M)

Division of Oto-Rhino-Laryngology, Jewish General Hospital, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada.

Michael Tamilia (M)

Division of Endocrinology and Metabolism, Jewish General Hospital, 3755, Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3Y 1E2, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH